GlaxoSmithKline plans to spin off its consumer healthcare division into a separate business by mid-2022. According to Bloomberg, the new company could be valued at $54 billion and sold to other industry players such as Advent, CVC and KKR. If the deal to sell the unit goes through, it would be the largest in the history of the stock market.